The Immunotherapy of Cancer Conference is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of.
Patients with HR-positive, HER2-negative high-risk early breast cancer tended to experience improved invasive disease and distant relapse-free survival after adding Verzenio to endocrine therapy.
Adjuvant treatment with the combination of abemaciclib and endocrine therapy (ET) maintained a benefit in invasive disease-free survival and distant relapse–free survival compared with ET alone in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer.